- Home
- SFHG vs TNGX Comparison
SFHG vs TNGX Comparison
Compare SFHG & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SFHG | TNGX |
|---|---|---|
| Founded | 1993 | 2014 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Publishing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.6M | 1.4B |
| IPO Year | 2024 | N/A |
Fundamental Metrics
Financial Performance| Metric | SFHG | TNGX |
|---|---|---|
| Price | $0.97 | $8.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $12.50 |
| AVG Volume (30 Days) | 172.2K | ★ 2.4M |
| Earning Date | 10-30-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $19,577,200.00 | ★ $66,501,000.00 |
| Revenue This Year | N/A | $52.80 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 3.56 | ★ 53.29 |
| 52 Week Low | $0.32 | $1.03 |
| 52 Week High | $2.32 | $11.20 |
Technical Indicators
Market Signals| Indicator | SFHG | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 78.30 | 45.46 |
| Support Level | $0.75 | $8.42 |
| Resistance Level | $0.99 | $8.98 |
| Average True Range (ATR) | 0.08 | 0.55 |
| MACD | 0.04 | -0.14 |
| Stochastic Oscillator | 93.88 | 22.47 |
Price Performance
Historical ComparisonAbout SFHG Samfine Creation Holdings Group Limited Ordinary Share
Samfine Creation Holdings Group Ltd operates through its subsidiaries. It is an established one-stop printing service provider which principally provides printing services in Hong Kong and the PRC. It offers a wide range of printed products such as (i) book products, which mainly include children's books, educational books, art books, notebooks, diaries and journals; and (ii) novelty and packaging products, which mainly include handcraft products, book sets, pop-up books, stationery products, products with assembly parts and other specialized products, shopping bags and package boxes.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.